创新链系列——中国创新药研发投入景气度指标2026年2月跟踪

Investment Rating - The industry investment rating is "Positive" and is maintained [11] Core Insights - The financing ecosystem for China's biopharmaceutical industry is gradually entering a positive cycle, driven by the influx of funds from A/H listings and capital increases of innovative drug companies. This is expected to improve the willingness to invest in R&D, leading to a new cycle of prosperity in the innovative drug industry [2][41] - The IPO channels for innovative drugs are widening, with significant fundraising observed. In February 2026, the fundraising amount for H-share pharmaceutical companies reached 3 billion yuan, and the total for January-February 2026 was 3.8 billion yuan, indicating a positive trend [6][30] - The overall fundraising scale for pharmaceutical companies through capital increases is also on an upward trend, with A-share pharmaceutical companies raising 500 million yuan in February 2026, a year-on-year increase of 138% [7][32] - The investment amount in China's biopharmaceutical sector is showing signs of recovery, with a total of 510 million USD in February 2026, a year-on-year increase of 287% [8][35] - The upfront payments from external business development (BD) have become a significant new source of funding for R&D, with February 2026 seeing an amount of 860 million USD, a year-on-year increase of 627% [9][39] Summary by Sections Innovative Drug R&D Investment Climate - The investment climate for innovative drug R&D in China is improving, driven by increased cash flow and a willingness to invest in R&D [23][41] IPO and Fundraising Trends - The IPO market for innovative drugs is experiencing a resurgence, with a notable increase in fundraising amounts for both H-share and A-share pharmaceutical companies [6][30][31] Capital Increase Activities - The trend of capital increases among pharmaceutical companies is positive, with significant year-on-year growth in fundraising amounts [7][32] Biopharmaceutical Investment Recovery - The biopharmaceutical investment amounts are on the rise, indicating a potential recovery in the investment ecosystem [8][35] External BD Payments - External BD upfront payments are emerging as a major funding source for R&D, significantly surpassing traditional investment amounts [9][39]